Radar · Life Sciences in Scotland
Best Life Sciences Companies in Scotland, United Kingdom
The 161 best Life Sciences companies in Scotland, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Resolution Therapeutics.
By Riya SenguptaFinancials
161companies tracked
$1.1Bdisclosed funding
0unicorns
84have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × SCOTLAND
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
62companies analysed
75%cloud-native stacks
2026funding peak (by rounds)
2unicorns
2016median founding year
85kcombined LinkedIn audience
32%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Scotland
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Resolution Therapeutics Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases | $120M | 20 mo ago | 6 | 2017 | John Campbell Co-Founder | Series B | 17 patents Patents concentrated in chemistry & materials | — |
| 2 | Trogenix Developer of precision cancer treatments using its proprietary gene therapy platform 55Funding top 23%Growth top 28%Talent top 38%Moat top 40% All 7 signals ▾Fundingtop 23% Growthtop 28% Talenttop 38% Moattop 40% Techbottom 47% Globalbottom 45% Marketbottom 35% Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $111M | 8 mo ago | — | 2023 | Steve Pollard Co-Founder | Series A | — | — |
| 3 | Pheno Therapeutics Developer of remyelinating therapies for multiple sclerosis | $75M | 51 mo ago | 2 | 2019 | Jon Moore CEO | Series A | — | — |
| 4 | NuCana Clinical-stage biopharmaceutical company developing novel nucleotide analogs to make chemotherapy agents… | $67M | 146 mo ago | 29 29 → 22 (-24%) | 2008 | Hugh Griffith CEO | Public | 530 patents Phosphoramidate prodrugs of nucleoside analogues for targeted cancer therapy | — |
| 5 | Enterobiotix Developer of microbiome-based therapeutics for multiple disease targets 50Growth top 13%Funding top 25%Product top 30%Moat top 39% All 11 signals ▾Growthtop 13% Fundingtop 25% Producttop 30% Moattop 39% Talentbottom 49% Globalbottom 42% Innovationbottom 41% Techbottom 41% Patentsbottom 37% Marketbottom 36% Newsbottom 22% Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $66M | 1 mo ago | 28 28 → 44 (+57%) | 2017 | James McIlroy Founder & CEO | Series B | 10 patents Medical sample collection containers for diagnostic testing | 1 award |
| 6 | Ardana Bioscience Therapeutics for reproductive disorders | $54M | 275 mo ago | 27 | 2000 | Ian Kent Founder | Series B | 53 patents Peptide drug delivery systems and growth‑hormone diagnostic kits | — |
| 7 | Mironid Molecules to modulate the activity of phosphodiesterase 4 (PDE4) enzymes to treat inflammatory disease and… | $45M | 33 mo ago | 12 12 → 16 (+33%) | 2015 | Neil Wilkie CEO | Series A | 32 patents Design and synthesis of novel PDE4-activating pharmaceutical compounds | — |
| 8 | Chemify Developer of a platform for digitizing chemistry and chemical discovery 64Growth top 20%Funding top 26%AI top 30%Tech top 40% All 11 signals ▾Growthtop 20% Fundingtop 26% AItop 30% Techtop 40% Talentbottom 49% Marketbottom 44% Globalbottom 42% Moatbottom 42% Patentsbottom 40% Innovationbottom 39% Newsbottom 17% Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $43.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 4 mo ago | 40 | 2020 | Lee Cronin Founder & CEO | Series B | 2 patents Modular catalytic reactors and networked chemical processing platforms for scalable synthesis | — |
| 9 | Nemaura Medical Provider of an AI-based blood-glucose monitoring system | $38M | 64 mo ago | 37 | 2011 | — | Public | — | — |
| 10 | Calcivis Developer of imaging systems for dental caries | $31M | 26 mo ago | 10 | 2011 | Gregory Sheehan CEO | Series B | 25 patents Optical detection of dental demineralization and caries using handheld devices. | — |
| 11 | M Squared Developer of light-sheet microscopy systems for multiple business verticals | $31M | 66 mo ago | 110 | 2006 | Vinor Zukhubaia Co-Founder | Series B | 10 patents AI-driven secure access control hardware and blockchain-based identity verification solutions. | — |
| 12 | TC Biopharm Developer of T-cell therapies for cancer and infectious disease treatment | $28M | 42 mo ago | 79 | 2013 | — | Public | 52 patents Patents concentrated in chemistry & materials | — |
| 13 | Cumulus Oncology Developer of therapies for treating cancers | $19M | 29 mo ago | 4 | 2017 | — | Seed | — | — |
| 14 | Lamellar Develops patented medical devices and pharmaceuticals based on mimetics of extra-alveolar lamellar bodies | $18M | 109 mo ago | 11 | 2007 | — | Series C | — | — |
| 15 | Pneumagen Developer of a treatment for viral respiratory tract infections and cancer | $18M | 36 mo ago | 7 | 2016 | Douglas Thomson CEO | Series A | 41 patents Antiviral therapeutics targeting RSV by sialic‑acid receptor binding inhibition | — |
| 16 | Vascular Flow Developer of Vascular devices based on spiral laminar flow technology | $17M | 89 mo ago | 10 10 → 10 (+0%) | 1998 | — | Series B | 37 patents Implantable vascular conduits, stents, and grafts for blood‑flow management | — |
| 17 | Mtem Developer of next-gen immunotoxins for cancer | $14M | 34 mo ago | 222 | 2004 | — | Acquired | 130 patents Marine electromagnetic subsurface surveying and resistivity measurement for underwater formation analysis | — |
| 18 | Invizius Developer of priming solutions for hemodialyzers | $13M | 20 mo ago | 12 12 → 9 (-25%) | 2018 | Richard Boyd CEO | Series A | 9 patents Complement inhibition therapeutics for peritoneal dialysis and diagnostic/therapeutic fusion proteins | — |
| 19 | Prothea Technologies Provider of lung cancer biopsy and treatments | $13M | 26 mo ago | — | 2024 | Crispin Simon CEO | Series A | — | — |
| 20 | Wobble Genomics Provider of a platform for discovery of nucleic acid biomarkers | $12M | 29 mo ago | 6 | 2020 | Richard Kuo Founder | Series A | 38 patents Normalization and amplification of single‑stranded nucleic acids for biomarker analysis | — |
| 21 | MedAnnex Monoclonal antibody for the treatment of autoimmune diseases | $12M | 81 mo ago | 9 | 2009 | — | Series B | 34 patents Antibody therapeutics targeting annexin A1 for cancer treatment | — |
| 22 | MGB Biopharma Developer of drugs for drug-resistant bacterial infections | $12M | 81 mo ago | 3 | 2010 | Raymond Spencer Founder | Series A | — | — |
| 23 | Macomics Developer of immnotherapies for treating cancer | $10M | 58 mo ago | 2 | 2018 | Jeffrey Pollard Co-Founder | Seed | 13 patents Gene editing vectors and macrophage-modulating therapeutics for cancer diagnostics and treatment. | — |
| 24 | Bsolve Dental Developer of dissolvable dental and oral strips | $10M | 91 mo ago | 37 | 2003 | — | Series A | — | — |
| 25 | Dxcover AI-powered device for earlier diagnosis of brain tumors | $9M | 16 mo ago | 16 16 → 31 (+94%) | 2016 | Holly Butler Co-Founder & Chief Technical Officer | Series A | 32 patents Early cancer detection via spectroscopic analysis of biological samples | — |
| 26 | Kynos Therapeutics Developer of therapies for immunological diseases | $8M | 50 mo ago | 2 | 2020 | Damian Mole Co-Founder | Acquired | — | — |
| 27 | ILC Therapeutics Developer of immunotherapeutics for the treatment cancer | $8M | 21 mo ago | 2 | 2012 | Bill Stimson Founder | Series A | 51 patents Patents concentrated in chemistry & materials | — |
| 28 | Nebu~Flow Developer of aerosol delivery platform technology | $8M | 25 mo ago | 11 | 2019 | Julien Reboud Co-Founder | Series A | — | — |
| 29 | Carcinotech Developer of 3D cancer research models for cancer drug discovery | $8M | 28 mo ago | 1 | 2018 | Ishani Malhotra CEO | Seed | 10 patents In‑vitro cancer model and microenvironment culture devices for tumor research | — |
| 30 | Cytomos POC cell sorter | $7M | 19 mo ago | 8 | 2012 | David Rigterink CEO | Series A | 32 patents Cellular analysis and biosensing instruments for measuring biological samples | — |
| 31 | Aurum Biosciences A biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI… | $6M | 28 mo ago | 6 | 2015 | — | Series A | 8 patents Assessing and imaging metabolic function using biomedical diagnostic methods | — |
| 32 | Lario Therapeutics Developer of therapeutics for the treatment of neurological disorders | $6M | 22 mo ago | — | 2021 | Henning Steinhagen Co-Founder & CEO | Funding Raised | 25 patents Cav2.3 calcium channel antagonists for neurodegenerative disease therapy | — |
| 33 | Glox Theraputics Developer of precision antibiotics to target antimicrobial resistant pathogens | $5M | 18 mo ago | — | 2023 | Colin Kleanthous Co-Founder | Seed | — | 1 award |
| 34 | Neurocentrx Developing products to treat chronic cancer pain. | $5M | 8 mo ago | 4 | 2013 | — | Seed | — | — |
| 35 | Chromacity Provider of tunable fiber lasers for industrial applications | $5M | 22 mo ago | 12 | 2013 | — | Seed | — | — |
| 36 | 1nhaler Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and… | $5M | 7 mo ago | — | 2017 | Don Smith Co-Founder | Seed | 39 patents Portable, foldable inhaler devices for delivering respiratory pharmaceuticals | — |
| 37 | Ocutec Developer of Polyethylene Glycol (PEG)-based ocular lens | $5M | 51 mo ago | 9 | 2001 | — | Seed | 77 patents Advanced polymer formulations and packaging for contact lenses | — |
| 38 | BioLiberty Provider of robotic assistance glove for handling hand weakness | $4M | 30 mo ago | 4 | 2020 | — | Series A | 11 patents Soft robotic assistive devices for medical rehabilitation and assistive technology | 1 job opening · 1 award |
| 39 | BioCaptiva Developer of liquid biopsy technology to detect cancer | $4M | 3 mo ago | 7 | 2018 | Jeremy Wheeler CEO | Seed | 9 patents Nucleic acid capture and isolation devices for clinical sample processing | — |
| 40 | Concinnity Provider of AI-driven platform for developing gene and cell therapies | $4M | 18 mo ago | — | 2021 | Jessica Birt Co-Founder & CEO | Seed | — | — |
| 41 | Microplate Dx Developer of a diagnostic test for drug-resistant infections | $4M | 9 mo ago | 12 | 2017 | Paul Hoskisson Co-Founder | Seed | 4 patents Detecting and quantifying microbial growth in microplate-based assay systems. | — |
| 42 | DestiNA Genomics Develops non-enzymatic nucleic acid detection technology | $3M | 43 mo ago | 2 | 2010 | Hugh Ilyine Co-Founder & CEO | Seed | 4 patents Ultra‑sensitive single‑molecule nucleic‑acid detection with base‑level specificity | 2 launchs |
| 43 | Nami Surgical Provider of ultrasonic scalpels for robotic-assisted surgery | $3M | 4 mo ago | — | 2021 | Rebecca Cleary Co-Founder & CTO | Series A | 7 patents Ultrasonic transducers for surgical instrumentation and therapeutic devices. | 1 job opening · 2 awards |
| 44 | 1nhaler Developer of single dose and portable inhaler for drug delivery | $3M | 30 mo ago | 2 | 2017 | Lisa McMyn Co-Founder & CEO | Seed | 39 patents Portable and foldable aerosol drug delivery inhaler devices | — |
| 45 | Biotangents Developer of diagnostic assays for infectious diseases in veterinary medicine | $3M | 18 mo ago | 13 | 2015 | — | Series A | 6 patents Molecular diagnostics: nucleic acid detection assays and sample‑prep instrumentation. | — |
| 46 | Neuranics Developer of magnetic sensing technology for next-generation wearable systems 21Talent top 38%Growth top 45%Moat top 47%Funding bottom 47% All 10 signals ▾Talenttop 38% Growthtop 45% Moattop 47% Fundingbottom 47% Patentsbottom 41% Globalbottom 40% Innovationbottom 31% Techbottom 31% Marketbottom 27% Newsbottom 21% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $2M | 14 mo ago | 10 | 2021 | Hadi Heidari Co-Founder & CTO | Seed | 2 patents Continuous cardiac arrhythmia monitoring using wearable sensor technology | 1 launch · 1 partnership |
| 47 | OGI Bio Provider of a system for automation of routine microbial culturing | $2M | 12 mo ago | 8 | 2020 | Teuta Pilizota Co-Founder | Seed | — | — |
| 48 | Metacarpal Developer of robotic upper-limb prosthetics 16Funding top 42%Moat top 45%Patents top 46%Innovation top 49% All 8 signals ▾Fundingtop 42% Moattop 45% Patentstop 46% Innovationtop 49% Talentbottom 49% Globalbottom 40% Techbottom 34% Marketbottom 15% Funding: Raised $1.1M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents rank vs industry peers · Fliar Intelligence Index 16/100 | $1M | 1 mo ago | 2 | 2020 | Fergal Mackie Co-Founder & CEO | Series A | 4 patents Advanced prosthetic hand and wrist devices for biomechanical rehabilitation | — |
| 49 | Lentitek Developer of technology to enhance lentiviral vector quality and yield | $309K | 15 mo ago | 3 | 2019 | Leif Anderson Co-Founder | Seed | 3 patents Design and production of genetic expression vectors for recombinant protein synthesis. | — |
| 50 | Green Bioactives Plant-based nutraceuticals for enhanced memory and cognition | $102K | 14 mo ago | 2 | 2019 | David Mcelroy Non-Exec. Director (2021-22) / CEO & Director (2022-Present) | Seed | 12 patents Isolation and application of plant stem cells for bioactive, cosmetic, and pharmaceutical products | — |
Top 12 Life Sciences companies in Scotland
#1
Series B · Edinburgh, Scotland · founded 2017 · 28 employees$66Mraised▾
Series B · Edinburgh, Scotland · founded 2017 · 28 employees
Developer of microbiome-based therapeutics for multiple disease targets. The company is engaged in developing an integrated anaerobic system which comprises of a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments. It aims to offer microbiome therapy to patients suffering from Inflammatory Bowel Disease and other diseases related to the gut.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Growth
top 13%Funding
top 25%Product
top 30%Moat
top 39%Talent
bottom 49%Global
bottom 42%Growth: Headcount 11 → 28 (+155%) across vintages · Fresh capital in last 24 mo
Funding: Raised $66.0M across 10 rounds · 10 rounds over 9 yrs (1.1/yr) · Last round Series B (Apr 2026)
Product: 4 distinct product lines · Company stage: Series B
Audience (LinkedIn): 8k LinkedIn followers — 9.4% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Series B$25M
- Mar 2026Series B$5.3M
- Jul 2025Series B$1.4M
- Mar 2024Series B$1.3M
Founders & team
Investors
Equity Gap, BWC, University of Aberdeen, Scottish Investment Bank, SIS Ventures, Syndicate Room
Tech stack
AngularApple Icloud MailCart FunctionalityCore-JsGodaddyHsts
#2
Series B · Glasgow, Scotland · founded 2020 · 40 employees$43Mraised▾
Series B · Glasgow, Scotland · founded 2020 · 40 employees
Developer of a platform for digitizing chemistry and chemical discovery. The platform combines chemistry, robotics, computation, machine learning, and a programming language to automate molecule creation. It aims to accelerate molecular discovery and bridge the gap between design and synthesis. The company focuses on developing novel compounds and materials.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Growth
top 20%Funding
top 26%AI
top 30%Tech
top 40%Talent
bottom 49%Market
bottom 44%Growth: Web rank 50,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Funding: Raised $43.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Feb 2026)
AI: Classified as an AI company · Product described with: machine learning
Audience (LinkedIn): 8k LinkedIn followers — 8.8% of this cohort's audience
Funding rounds
- Feb 2026Series B—
- Dec 2025Grant (prize money)$1.6M
- Oct 2025Series B$50M
- Oct 2024Grant (prize money)—
Founders & team
Investors
Gates, Triatomic, Horizons Ventures, Rocketship, Possible Ventures, Alix Ventures
Tech stack
Apple Icloud MailCloudflareCookiebotHstsHttp/3Jquery
#3
Series A · Edinburgh, Scotland · founded 2023$111Mraised▾
Series A · Edinburgh, Scotland · founded 2023
Developer of precision cancer treatments using its proprietary gene therapy platform. It leverages proprietary Synthetic Super-Enhancers technology, delivered via Adeno-Associated Virus vectors. It offer therapies for glioblastoma, colorectal cancer, hepatocellular carcinoma, lung squamous cell cancer, and fibrosis.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 23%Growth
top 28%Talent
top 38%Moat
top 40%Tech
bottom 47%Global
bottom 45%Funding: Raised $111M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) · Last round Series A (Oct 2025)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 3k LinkedIn followers — 3.7% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series A$95M
- Aug 2024Series A$11.5M
- Feb 2024Series A$4.4M
Founders & team
Investors
IQ Capital, 4Bio Capital, Lilly, Meltwind Advisory, LongeVC, Calculus Capital
Tech stack
Animate.CssAnime.JsCookieyesExactmetricsFancyboxGodaddy
#4
Seed · Edinburgh, Scotland · founded 2018 · 7 employees$4Mraised▾
Seed · Edinburgh, Scotland · founded 2018 · 7 employees
Developer of liquid biopsy technology to detect cancer. The company's technology sequences cfDNA isolated from the patient's blood and helps in genome analysis for monitoring and detecting cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Seed$2.1M
- Jun 2022Seed$2.6M
- Apr 2021Seed$1.4M
Founders & team
Investors
Archangels, Scottish Enterprise, Cancer Research Horizons, Old College Capital, BBI Capital, EverQuest Capital
#5
Series A · Glasgow, Scotland · founded 2021$3.1Mraised▾
Series A · Glasgow, Scotland · founded 2021
Provider of ultrasonic scalpels for robotic-assisted surgery. The company develops high-performance miniaturised ultrasonic scalpels for Robotic Assisted Surgery widely used in various surgical procedures such as urology, gynaecology, and cardiology.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers — 2.5% of this cohort's audience
Hiring: 1 hiring post in 12 mo (public) · hiring: Technical R&D Engineer
Activity: 2 awards announced in 12 mo
Funding rounds
- Jan 2026Series A$2.6M
- Aug 2025Series A$10M
- May 2024Seed$3.1M
- May 2024Grant (prize money)$877.5K
Founders & team
Investors
Eos Advisory, Maven Capital Partners, SIS Ventures, Scottish Enterprise, British Business Bank, Ukri
Tech stack
AosCloudflareCloudflare Bot ManagementFont AwesomeGodaddyGoogle Analytics
#6
Series B · Edinburgh, Scotland · founded 2017 · 6 employees$119.9Mraised▾
Series B · Edinburgh, Scotland · founded 2017 · 6 employees
Developer of macrophage cell therapy for the treatment of inflammatory & liver diseases. The company has developed cell therapies based on its proprietary platform of macrophage biology, cell engineering, and manufacturing processes. The therapeutic solutions enhance body immunity power and provide prevention solutions for inflammatory organ damages. It also helps in sterilising any wounds and promotes organ repair.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 12k LinkedIn followers — 13.7% of this cohort's audience
Funding rounds
- Oct 2024Series B$84.3M
- Dec 2020Series A$35.6M
Founders & team
Investors
Syncona
Tech stack
All In One SeoAosApple Icloud MailContact Form 7CookieyesCore-Js
#7
Seed · Edinburgh, Scotland · founded 2017$4.7Mraised▾
Seed · Edinburgh, Scotland · founded 2017
Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons. It offers a portable inhaler made from cardboard and it folds from a flat, credit‑card shape into a 3D inhaler activated by a single breath. The lead project is salbutamol for asthma relief.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Nov 2025Seed$2M
- Nov 2023Seed$2.5M
- Mar 2022Seed$99.2K
- Apr 2019Seed$130.8K
Founders & team
Investors
British Business Investments, Archangels, Scottish Enterprise, British Business Bank
#8
Series A · Edinburgh, Scotland · founded 2020 · 2 employees$1.1Mraised▾
Series A · Edinburgh, Scotland · founded 2020 · 2 employees
Developer of robotic upper-limb prosthetics. It offers body-powered hand for restoring the functional and psychological needs of amputees.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
Funding
top 42%Moat
top 45%Patents
top 46%Innovation
top 49%Talent
bottom 49%Global
bottom 40%Funding: Raised $1.1M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 4 patents
Patents: 4 patents matched (strict assignee match) · 4 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers — 2.8% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2026Series A$2.7M
- Aug 2024Seed$1.1M
Founders & team
Investors
SIS Ventures, Scottish Enterprise, Worth Capital, University of Strathclyde, Gabriel, Oxford Technology
#9
Seed · Edinburgh, Scotland · founded 2013 · 4 employees$5Mraised▾
Seed · Edinburgh, Scotland · founded 2013 · 4 employees
Neurocentrx, a speciality pharma company, is developing pain management solutions to alleviate chronic, neuropathic and cancer pain. The company is developing new delivery formats for existing drugs. Its first product in development is an oral capsule form of an existing drug currently available in IV or oral liquid format. Other products in development are intended to help burning sensations felt in chemotherapy-induced peripheral neuropathy (CIPN), by developing topical products.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 991 LinkedIn followers
Funding rounds
- Sep 2025Grant (prize money)$5M
- Sep 2025Seed—
- Mar 2014Angel—
Investors
Equity Gap, Scottish Investment Bank, Wellcome, o2h ventures, Neo Kuma Ventures, SPRIM Global Investments
#10
Seed · Glasgow, Scotland · founded 2017 · 12 employees$3.7Mraised▾
Seed · Glasgow, Scotland · founded 2017 · 12 employees
Developer of a diagnostic test for drug-resistant infections. It offers a Rplate platform that combines hardware with data processing algorithms to perform rapid antibiotic susceptibility tests for urinary tract infections.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Sep 2025Conventional Debt—
- Sep 2025Seed$644.6K
- Sep 2023Seed$3.1M
- Dec 2022Seed$610.2K
Founders & team
Investors
Deepbridge Capital, University of Strathclyde, Scottish Enterprise, SIS Ventures, Scottish EDGE, Converge Challenge
#11
Series A · Glasgow, Scotland · founded 2016 · 16 employees$9.2Mraised▾
Series A · Glasgow, Scotland · founded 2016 · 16 employees
AI-powered device for earlier diagnosis of brain tumors. The company's platform combines novel hardware with AI algorithms to develop Dxcover to analyze blood and detect the commonly occurring cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 3.7% of this cohort's audience
Funding rounds
- Feb 2025Series A$6.2M
- 2023Grant (prize money)$2.8M
- Feb 2023Series A$9.2M
- Dec 2022Grant (prize money)$2.7M
Founders & team
Investors
EIC Fund, Europa, Norcliffe Capital, SIS Ventures, University of Strathclyde, Scottish Enterprise
#12
Series A · Edinburgh, Scotland · founded 2018 · 12 employees$13.1Mraised▾
Series A · Edinburgh, Scotland · founded 2018 · 12 employees
Developer of priming solutions for hemodialyzers. The product which is under development, H-Guard, a priming solution for hemodialyzer. It is made of up of the hemocompatible coating capable of preventing the blood's foreign body reactions during dialysis. The applications of the product the hollow fibers in dialyzers would reduce the inflammation of the membrane on the patient's blood.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Sep 2024Series A$1.3M
- Mar 2022Grant (prize money)$1.3M
- May 2021Series A$7.4M
- Feb 2020Seed—
Founders & team
Investors
Mercia, Downing, Old College Capital, Scottish Enterprise, Solvay, Calculus Capital
Tech stack
JimdoNginxHstsOpen Graph
Funding & investor landscape
$1.1Btotal disclosed funding
82companies funded
267disclosed rounds
2rounds last 90 days
Most active investors
Notable founders
James McIlroy
Founder & CEO · Enterobiotix
Lee Cronin
Founder & CEO · Chemify
Steve Pollard
Co-Founder · Trogenix
Ken Macnamara
Co-Founder & CEO · Trogenix
Jeremy Wheeler
CEO · BioCaptiva
Rebecca Cleary
Co-Founder & CTO · Nami Surgical
Nico Fenu
Co-Founder & CEO · Nami Surgical
John Campbell
Co-Founder · Resolution Therapeutics
Stuart Forbes
Co-Founder · Resolution Therapeutics
Don Smith
Co-Founder · 1nhaler
Lisa McMyn
Co-Founder & CEO · 1nhaler
Fergal Mackie
Co-Founder & CEO · Metacarpal
Prism market signals · United Kingdom · country-scoped Prism corpus, 709,332 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH FROM Scotland · institutions
What Scotland researches in biotechnology
Scotland's Rural College and partners cautiously advance livestock genetics, plant diversity mapping, and ruminant nutrition research, with a moderately optimistic stance amid some environmental contamination concerns.
22 papersstance +0.3019% breakthrough25% concern
local research themes
Genetic and phenotypic traits in livestockGenetic Mapping and Diversity in Plants and AnimalsRuminant Nutrition and Digestive PhysiologyFecal contamination and water qualityAgriculture Sustainability and Environmental ImpactBacterial Identification and Susceptibility Testing
top institutions
- Scotland\'s Rural College14
- University of the West of Scotland4
- Biomathematics and Statistics Scotland3
- Cancer Research UK Scotland Institute1
Common questions
How many Life Sciences companies are there in Scotland, United Kingdom?
Radar tracks 161 indexable Life Sciences companies headquartered in Scotland, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Scotland, United Kingdom?
The Life Sciences companies in Scotland, United Kingdom on this list have raised a combined $1.1B in disclosed equity funding across 82 funded companies.
Which is the highest-funded Life Sciences company in Scotland, United Kingdom?
Resolution Therapeutics is the highest-funded Life Sciences company in Scotland, United Kingdom, with $119.9M in disclosed equity funding.
How many Life Sciences companies in Scotland, United Kingdom are funded?
82 of the 161 Life Sciences companies in Scotland, United Kingdom on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Scotland, United Kingdom?
None of the Life Sciences companies in Scotland, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Scotland, United Kingdom Life Sciences companies?
The most active investors in Scotland, United Kingdom Life Sciences companies on this list include Scottish Enterprise, Europa, Archangels, Eos Advisory, Old College Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.